Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CTXR 
Citius Pharmaceuticals Inc (CTXR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/03/2025: CTXR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.53% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 29.19M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 2 | Beta 1.41 | 52 Weeks Range 0.65 - 12.84 | Updated Date 11/3/2025 |
52 Weeks Range 0.65 - 12.84 | Updated Date 11/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.85 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.88% | Return on Equity (TTM) -54.7% |
Valuation
Trailing PE - | Forward PE 3.59 | Enterprise Value 18418739 | Price to Sales(TTM) - |
Enterprise Value 18418739 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.74 | Shares Outstanding 18472191 | Shares Floating 15213662 |
Shares Outstanding 18472191 | Shares Floating 15213662 | ||
Percent Insiders 3.09 | Percent Institutions 13.89 |
Upturn AI SWOT
Citius Pharmaceuticals Inc
Company Overview
History and Background
Citius Pharmaceuticals, Inc. was founded in 2007. It is a late-stage biopharmaceutical company focused on developing and commercializing critical care products.
Core Business Areas
- Mino-Lok: An antibiotic lock solution used to salvage central venous catheters (CVCs) in patients with catheter-related bloodstream infections (CRBSIs). Currently awaiting FDA approval following positive Phase 3 results.
- Halo-Lido: A topical formulation of halobetasol and lidocaine being developed for the relief of hemorrhoids. Currently in Phase 2b trial.
- CITI-002 (Mesenchymal Stem Cell Therapy): An induced mesenchymal stem cell (iMSC) therapy for Acute Respiratory Distress Syndrome (ARDS). In preclinical stage.
Leadership and Structure
Leonard Mazur is the Chairman and CEO. Myron Holubiak is the CEO of the affiliated NoveCite. The company has a typical organizational structure with departments such as R&D, clinical operations, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- Halo-Lido: A topical formulation of halobetasol and lidocaine being developed for the relief of hemorrhoids. Currently in Phase 2b trial. Market size of hemmorhoid treatment is $1.4 billion in 2024 and expecting to grow to $1.77 billion by 2029. Some competitors would be Preparation H by Pfizer and Tucks Medicated Pads by Dickinson Brands.
- Mino-Lok: An antibiotic lock solution designed to salvage infected CVCs. Mino-Lok is still under FDA review. There is no current market share data available yet. Competitors would be other antibiotic lock therapies or the traditional removal and replacement of the CVC, and other antibiotics to treat infection.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, facing challenges related to regulatory approvals, clinical trial success rates, and market access. There is a high unmet need in critical care.
Positioning
Citius Pharmaceuticals is positioned as a specialty pharmaceutical company focused on developing niche products for unmet medical needs in critical care and adjunct cancer care.
Total Addressable Market (TAM)
The TAM for CRBSIs and hemorrhoid treatment is substantial. For CRBSIs it is estimated at ~$1.8 Billion in the US. For hemorrhoid treatment it is $1.4 Billion in 2024 and expecting to grow to $1.77 billion by 2029. Citius is positioned to capture a share of these markets with its pipeline of products.
Upturn SWOT Analysis
Strengths
- Late-stage product pipeline (Mino-Lok)
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Reliance on successful FDA approval for key products
- Limited revenue stream until product commercialization
- Relatively small market capitalization
Opportunities
- FDA approval and successful commercialization of Mino-Lok
- Expansion of product pipeline through acquisitions or in-licensing
- Partnerships with larger pharmaceutical companies
Threats
- Failure to obtain FDA approval for Mino-Lok
- Competition from other pharmaceutical companies
- Unfavorable changes in regulatory landscape
Competitors and Market Share
Key Competitors
- PFE
- VRX
Competitive Landscape
Citius faces competition from larger pharmaceutical companies with established products in the infection control and supportive care markets. Citius' advantage lies in its focus on niche, underserved areas, but its smaller size poses a challenge.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company being in the clinical development stage with no products on the market. Please consult SEC filings (10-K and 10-Q reports) for detailed financial data.
Future Projections: Future growth depends heavily on the successful approval and commercialization of Mino-Lok. Analyst estimates vary, but the consensus is contingent on regulatory success.
Recent Initiatives: Recent initiatives include advancing Mino-Lok through the FDA approval process, progressing Halo-Lido into Phase 2b trials, and pre-clinical research for CITI-002
Summary
Citius Pharmaceuticals is a clinical-stage biopharmaceutical company with potential in Mino-Lok. Successful FDA approval and commercialization of its products are critical. The company's smaller size and reliance on future product approvals represent risks, but focus on unmet needs is an advantage. They must also look out for competitors with similar products and unfavorable regulatory landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Citius Pharmaceuticals' Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company-specific events can significantly impact future performance. Market share are estimates based on available information and relevant markets, and are subject to variation.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Citius Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Cranford, NJ, United States | ||
IPO Launch date 2017-07-06 | Co-Founder, CEO, Chairman & Secretary Mr. Leonard L. Mazur | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://citiuspharma.com |
Full time employees 23 | Website https://citiuspharma.com | ||
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.